SANTA MONICA, Calif., May 15 /PRNewswire-FirstCall/ -- Cord Blood America, Inc. (BULLETIN BOARD: CBAI) , the umbilical cord blood stem cell preservation company (http://www.cordblood-america.com/) focused on bringing the life saving potential of stem cells to families nationwide and internationally, said today that Company founder and CEO Matthew Schissler, in a FirstCall In audio interview with analyst Francis Gaskins, explains the thought process behind the Company owning its own stem cell laboratory.
The interview and associated web links are available at http://www.investorcalendar.com/IC/ClientPage.asp?ID=145109.
An analyst report compiled by Mr. Gaskins, which details Cord Blood America's effort to become cash flow positive this year, is available at http://gaskinsco.com/linkto-cbai.shtml
"The laboratory will allow Cord Blood America to store the cells of its clients, potentially saving a tremendous amount of money in the long run," Mr. Schissler said. "Also, it allows CBAI to sell storage services to other cryogenic tissue storage companies, and allows Cord Blood America to diversify its stem cell storage base, opening up the market greatly. This vertical integration will create a competitive advantage for the Company."
For further updated information, please follow Cord Blood America at http://twitter.com/StemCellBanking, http://twitter.com/cbai, and http://stem-cell-banking.blogspot.com/ .
About Cord Blood America
Cord Blood America (BULLETIN BOARD: CBAI) is the parent company of CorCell, which facilitates umbilical cord blood stem cell preservation for expectant parents and their children. Its mission is to be the most respected stem cell preservation company in the industry. Collected through a safe and non-invasive process, cord blood stem cells offer a powerful and potentially life-saving resource for treating a growing number of ailments, including cancer, leukemia, blood, and immune disorders. To find out more about Cord Blood America, Inc. (BULLETIN BOARD: CBAI) , visit our website at http://www.corcell.com/. For investor information, visit http://www.cordblood-america.com/.
Forward-Looking Statements
Some statements made in this press release are forward-looking statements, which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. We use words such as "anticipate," "believe," "expect," "future," "intend," "plan," and similar expressions to identify forward-looking statements. These statements including those related to the growth of the industry, new stem cell treatments, and the Company's performance, are only predictions and are subject to certain risks, uncertainties and assumptions. Additional risks are identified and described in the Company's public filings with the Securities and Exchange Commission. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. The Company's past performance is not necessarily indicative of its future performance. The Company does not undertake, and the Company specifically disclaims any obligation to update any forward-looking statements to reflect occurrences, developments, events, or circumstances after the date of such statement.
CONTACT: Paul Knopick E & E Communications 949/707-5365 pknopick@eandecommunications.com
Cord Blood America, Inc.
CONTACT: Paul Knopick of E & E Communications, +1-949-707-5365,
pknopick@eandecommunications.com, for Cord Blood America, Inc.
Web Site: http://www.cordblood-america.com/
http://www.corcell.com/
